325902
FKBP12, GST-Fusion, Human, Recombinant, E. coli
FK506 binding protein 1A, 12 kDa, FKBP1A
For general questions please contact our Customer Service:
EMD Millipore
290 Concord Road
01821 Billerica, MA
United States
Phone: 781 533-6000
Fax: +49 6151 72 2000
E-mail: Customer.CareDesk@emdchemicals.com
25 May 2012
loading
| Product information | |||
|---|---|---|---|
| Form | Liquid | ||
| Formulation | In PBS, 10% glycerol, pH 7.2. | ||
| Molar mass | 38000 | ||
| Avoid freeze/thaw | Yes | ||
| Purity | ≥90% by SDS-PAGE | ||
| Store and ship information | |||
|---|---|---|---|
| Storage | ≤ -70°C | ||
| Ship |
Dry Ice Only
Standard Handling |
||
| Data | |||
|---|---|---|---|
![]() The activity of mTOR was assessed without inhibitor and in the presence of rapamycin alone (Cat. No. 553210), FKBP12 alone (Cat. No. 325902), FKBP12/rapamycin complex, and Wortmannin (Cat. No. 681675), using the K-LISA™ mTOR Activity Kit (Cat. No. CBA055) as outlined in the Detailed Protocol. The FKBP12/rapamaycin inhibitor complex was pre-assembled by mixing 62.5 µg/ml FKBP12 and 50 µM rapamycin on ice for 10 min. The mTOR Standard (50 µl) was incubated for 15 min on ice with FKBP12 (2 µl: final concentration 2.5 µg/ml), rapamycin (2 µl; final concentration 2 µM). FKPP12/rapamycin complex (final concentration 2.5 µg/ml, 2 µM rapamycin) or wortmannin (final concentration 10 µM). The kinase reaction was initiated by transferring each mixture to a corresponding well containing 2X kinase buffer and ATP. The results were assessed as outlined in the user protocol. |






